BE 

About

BrightEdge propels groundbreaking patient-centric solutions by accelerating the ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.

About

BrightEdge propels groundbreaking patient-centric solutions by accelerating the ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.

Our Mission

Leading the fight for a world without cancer.
BrightEdge operates at the intersection of impact, innovation, and investment to accelerate the American Cancer Society’s goal to reduce cancer mortality.
Our Connection
BrightEdge builds on the American Cancer Society’s role of funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies.
American Cancer Society Logo

$5.0b+

Invested in Research Since 1946

49

Noble Laureates

31%

Decline in Mortality Rate Since 1991

Investing for Real Impact

BrightEdge is a philanthropic impact investment fund, meaning that the financial returns realized from investments are returned to the American Cancer Society. Donations to BrightEdge will become a sustainable source of financial support to the American Cancer Society that is providing needed services in more than 5,000 local communities. Investment returns from the BrightEdge portfolio are both reinvested in the BrightEdge fund and used to sustain American Cancer Society’s life-saving programs in research, access, and health equity.

BrightEdge Portfolio Companies are...

  • Attacking Cancer

    Propelling groundbreaking patient-centric solutions to accelerate the ACS’s mission to advance science, reduce disparities, and promote healthcare sustainability.

  • Focused on Health Equity

    Seeking to broaden and accelerate patient access to life-saving innovations by developing technology-enabled solutions that will transform the way healthcare is delivered and experienced.

  • In All Stages of Development

    Stage-agnostic as BrightEdge will invest in seed-stage companies, businesses raising crossover rounds, and everything in between.

  • Funded by Industry-Leading VCs

    BrightEdge invests alongside the industry’s top VC funds to accelerate the most innovative companies that are raising capital through equity or convertible debt. (Note that while ACS Research distributes over one hundred million dollars of translational grants per year, the BrightEdge fund does not provide grant funding.)